Population‐based Mechanistic Assessment of Drugs Pro arrhythmic Potency Using In‐vitro and In‐vivo Extrapolation Approach.
The aim of the workshop is to present how mechanistic M&S can be used for the assessment of a drug’s pro-arrhythmic potency within target populations. Cardiac Safety Simulator can be used in the early stage of the drug development as a screening tool even in situations where no in-vitro data are available, or later at the clinical level to assess drug-drug or drug-physiology interactions.
The case studies will cover various elements of cardiac safety assessment including in vitro ion channels inhibition, clinical surrogates of cardiac safety and role of population variability all within the framework of simulated clinical trials. Participants will learn how to choose the most suitable models and also investigate the impact of various relevant assumptions on model performance.
Key aspects covered in this course:
- Quick overview of models within the Simcyp CSS
- What are the most appropriate in vitro data for the cardiac safety testing and their simulation
- Application of population models for the drug-physiology interaction assessment
By completing/passing this course, you will attain the certificate Certificate of Completion - CSS
Your cart is empty